The US Food and Drug Administration (FDA) has declined to approve Applied Therapeutics’ govorestat for classic galactosemia, prolonging the wait for the first marketed treatment for the genetic ...
The CDR1α and CDR3α loops of the iNKT TCR and the galactose headgroup of the α-GalCer analogues generally adopted very similar positions within all the ternary complexes and subtle changes in the ...
Originally based on molecular addon from pyroevil. https://github.com/Pyroevil/Blender-Molecular-Script and the efforts of PavelBlend and Scorpion81 for maintaining ...
TamGen offers a new approach to drug discovery by applying the principles of generative AI to molecular design. Unlike traditional methods, which depend on systematically screening known compounds—a ...
The deadline for the FDA’s verdict is Nov. 28. With around 3,000 diagnosed cases in the U.S., galactosemia is a rare, genetic and metabolic disorder characterized by the impaired or complete lack of ...